Antiplatelet Therapy

13 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Cardiology

Multilevel Stewardship to Optimize Antithrombotic Therapy in DOAC Users: Lessons from a Veterans Health Initiative

By MedXY|Jun 25, 2026

A multicomponent stewardship intervention significantly reduced inappropriate antiplatelet prescription among patients on DOACs, decreasing bleeding risk, particularly in stable coronary artery disease.

Cardiology

Antiplatelet Therapy

Latest news

Multilevel Stewardship to Optimize Antithrombotic Therapy in DOAC Users: Lessons from a Veterans Health Initiative

Optimizing Antiplatelet Strategies in Complex PCI: Insights from the TAILORED-CHIP Trial and Evolving Evidence for Temporal Modulation

High Insulin Resistance Blunts the Superiority of Ticagrelor Over Clopidogrel in Minor Stroke Patients with CYP2C19 Mutations

Aspirin vs. Clopidogrel Beyond 30 Days Post-PCI: Equivalent Outcomes Regardless of Oral Anticoagulation Status

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS

Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial

Clopidogrel versus Aspirin for Secondary Prevention in Coronary Artery Disease: A Comprehensive Meta-Analysis

Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

Antiplatelet vs Anticoagulant Therapy in Embolic Stroke of Undetermined Source: Insights from a Large Multicenter Cohort Study

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial